Validating visual evoked potentials as a preclinical, quantitative biomarker for remyelination efficacy

Area of Science:

• Neuroscience
• Pathology
• Clinical Neurology

Background:

• Biomarkers in clinical neuroscience often lack pathological validation, hindering therapeutic development for neurological diseases.
• Despite promising remyelinating candidates, validated methods to assess therapeutic efficacy in the central nervous system (CNS) are needed.
• Remyelination therapies are crucial for treating multiple sclerosis and other demyelinating diseases.

Purpose of the Study:

• To validate visual evoked potential (VEP) as a quantitative tool for assessing myelin repair in the CNS.
• To establish a biologically specific method for preclinical verification of remyelination therapies.

Main Methods:

• Correlating histopathological and ultrastructural measures of myelination with VEP latency in inflammatory and chemical demyelination models.
• Assessing the effect of clemastine, a remyelinating compound, on VEP latency and myelin status.
• Utilizing a transgenic animal model incapable of myelin formation to confirm VEP specificity.

Main Results:

• Quantitative myelination assessments corresponded with VEP latency in demyelination models.
• Clemastine treatment improved VEP latency, mirroring improvements in myelin assessment.
• VEP latency did not improve with clemastine in animals unable to form new myelin, confirming VEP's link to remyelination.

Conclusions:

• Visual evoked potential is a validated tool for preclinical assessment of remyelination.
• VEP provides a reliable measure of myelin status, crucial for advancing therapies for demyelinating diseases.